Buprenorphine-naloxone Therapy in Pain Management

Overview

Journal Anesthesiology

Specialty Anesthesiology

Date 2014 Feb 11

PMID 24509068

Citations 50

Authors

Kelly Yan Chen

Lucy Chen

Jianren Mao

Affiliations

Soon will be listed here.

Abstract

Buprenorphine-naloxone (bup/nal in 4:1 ratio; Suboxone; Reckitt Benckiser Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug Administration for outpatient office-based addiction treatment. In the past few years, bup/nal has been increasingly prescribed off-label for chronic pain management. The current data suggest that bup/nal may provide pain relief in patients with chronic pain with opioid dependence or addiction. However, the unique pharmacological profile of bup/nal confers it to be a weak analgesic that is unlikely to provide adequate pain relief for patients without opioid dependence or addiction. Possible mechanisms of pain relief by bup/nal therapy in opioid-dependent patients with chronic pain may include reversal of opioid-induced hyperalgesia and improvement in opioid tolerance and addiction. Additional studies are needed to assess the implication of bup/nal therapy in clinical anesthesia and perioperative pain management.

Citing Articles

Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting.

Kohan L, Barreveld A, Potru S, Abd-Elsayed A, Viscusi E Pain Pract. 2024; 25(1):e13427.

PMID: 39450825 PMC: 11683522. DOI: 10.1111/papr.13427.

Navigating opioid use in chronic noncancer pain conditions: A case series on pseudoaddiction.

Dhagudu N, Brar M, George A, Ambekar A Indian J Psychiatry. 2024; 66(7):668-671.

PMID: 39257500 PMC: 11382757. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_69_24.

Sublingual buprenorphine-naloxone microdosing protocol to wean and explant intrathecal drug delivery systems for chronic non-cancer pain.

Wong V, Osborn J, Varshney V Interv Pain Med. 2024; 2(2):100258.

PMID: 39238660 PMC: 11373072. DOI: 10.1016/j.inpm.2023.100258.

Nanotechnology-Enhanced Naloxone and Alternative Treatments for Opioid Addiction.

Heyns I, Faunce A, Mumba M, Kumar M, Arora M ACS Pharmacol Transl Sci. 2024; 7(8):2237-2250.

PMID: 39144549 PMC: 11320732. DOI: 10.1021/acsptsci.4c00158.

Low-Dose Buprenorphine Initiation for Hospitalized Patients With Chronic Pain and Opioid Use Disorder or Opioid Misuse: Protocol for an Open-Label, Parallel-Group, Effectiveness-Implementation Randomized Controlled Trial.

Hayes B, Sanchez Fat G, Torres-Lockhart K, Khalid L, Minami H, Ghiroli M Subst Use Addctn J. 2024; 46(1):184-191.

PMID: 39068540 PMC: 11652261. DOI: 10.1177/29767342241263221.

References

Fiellin D, Moore B, Sullivan L, Becker W, Pantalon M, Chawarski M . Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008; 17(2):116-20. DOI: 10.1080/10550490701860971. View

Pade P, Cardon K, Hoffman R, Geppert C . Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model. J Subst Abuse Treat. 2012; 43(4):446-50. DOI: 10.1016/j.jsat.2012.08.010. View

Kroutil L, Van Brunt D, Herman-Stahl M, Heller D, Bray R, Penne M . Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006; 84(2):135-43. DOI: 10.1016/j.drugalcdep.2005.12.011. View

Mao J . Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002; 100(3):213-217. DOI: 10.1016/S0304-3959(02)00422-0. View

Davis M, Walsh D . Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001; 9(2):73-83. DOI: 10.1007/s005200000180. View

Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y . Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci. 1995; 56(15):PL285-90. DOI: 10.1016/0024-3205(95)00078-x. View

Leander J . Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 1987; 26(9):1445-7. DOI: 10.1016/0028-3908(87)90112-2. View

Pfeiffer A, BRANTL V, Herz A, Emrich H . Psychotomimesis mediated by kappa opiate receptors. Science. 1986; 233(4765):774-6. DOI: 10.1126/science.3016896. View

Breivik H, Ljosaa T, Stengaard-Pedersen K, Persson J, Aro H, Villumsen J . A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scand J Pain. 2018; 1(3):122-141. DOI: 10.1016/j.sjpain.2010.05.035. View

10.

Caplehorn J, Drummer O . Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002; 26(4):358-62; discussion 362-3. DOI: 10.1111/j.1467-842x.2002.tb00185.x. View

11.

Levine J, Gordon N, Fields H . Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature. 1979; 278(5706):740-1. DOI: 10.1038/278740a0. View

12.

Daitch J, Frey M, Silver D, Mitnick C, Daitch D, Pergolizzi Jr J . Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012; 15(3 Suppl):ES59-66. View

13.

Darke S, Duflou J, Torok M . The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2009; 106(1):1-6. DOI: 10.1016/j.drugalcdep.2009.07.014. View

14.

Griessinger N, Sittl R, Likar R . Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005; 21(8):1147-56. DOI: 10.1185/030079905X53315. View

15.

Alho H, Sinclair D, Vuori E, Holopainen A . Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2006; 88(1):75-8. DOI: 10.1016/j.drugalcdep.2006.09.012. View

16.

Schackman B, Leff J, Polsky D, Moore B, Fiellin D . Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012; 27(6):669-76. PMC: 3358393. DOI: 10.1007/s11606-011-1962-8. View

17.

Toblin R, Mack K, Perveen G, Paulozzi L . A population-based survey of chronic pain and its treatment with prescription drugs. Pain. 2011; 152(6):1249-1255. DOI: 10.1016/j.pain.2010.12.036. View

18.

Bryson E, Lipson S, Gevirtz C . Anesthesia for patients on buprenorphine. Anesthesiol Clin. 2010; 28(4):611-7. DOI: 10.1016/j.anclin.2010.08.005. View

19.

Raisch D, Fye C, Boardman K, Sather M . Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002; 36(2):312-21. DOI: 10.1345/aph.10421. View

20.

Neumann A, Blondell R, Jaanimagi U, Giambrone A, Homish G, Lozano J . A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013; 32(1):68-78. PMC: 3604999. DOI: 10.1080/10550887.2012.759872. View